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Protein degradation is an essential process that continuously
takes place in all living cells. Regulated degradation of most cel-
lular proteins is initiated by proteasomes, which produce pep-
tides of varying length. These peptides are rapidly cleaved to
single amino acids by cytoplasmic peptidases. Proline-contain-
ing peptides pose a specific problemdue to structural constrains
imposed by the pyrrolidine ring that prevents most peptidases
from cleavage. Here we show that DPP9, a poorly characterized
cytoplasmic prolyl-peptidase, is rate-limiting for destruction of
proline-containing substrates both in cell extracts and in intact
cells. We identified the first natural substrate for DPP9, the
RU134–42 antigenic peptide (VPYGSFKHV). RU134–42 is
degraded in vitro by DPP9, and down-regulation of DPP9 in
intact cells results in increased presentation of this antigen.
Together our findings demonstrate an important role for DPP9
in peptide turnover and antigen presentation.
Protein turn-over is an essential process that continuously
occurs in all living cells. The ubiquitin-proteasome system is
responsible for initiating the regulated degradation ofmost cel-
lular proteins (1). Proteasome-degradation products are not sin-
gle amino acids but rather peptides varying in length between 3
and 22 amino acids (2, 3). Cytosolic amino- and endopeptidases
rapidly cleave these peptides (4) to allow recycling of amino acids
and to prevent accumulation of short peptides, which may be
harmful to the cell. In addition, these peptidases also play an
important role in the trimming of proteasomal products for anti-
gen presentation onMHC4 class I (5–8).
Peptides containing proline residues pose a problem formost
peptidases due to the pyrrolidine ring of proline that gives it an
exceptional conformational rigidity. Only few peptidases are
known to cleave after prolines, including the cytoplasmic pep-
tidases prolyl oligopeptidase (POP) and cytoplasmic members
of the S9B/DPPIV family (DPP8 and DPP9). POP is a cytosolic
endopeptidase of the S9A family, which is broadly distributed
with high concentrations in the brain. It has been implicated in
the maturation and degradation of peptide hormones and neu-
ropeptides (9, 10).
S9B/DPPIV peptidases are a family of exopeptidases that
cleave off N-terminal dipeptides from proteins/polypeptides
having a proline residue at the second position (Xaa-Pro). The
best-characterized member of this family is DPPIV, a mem-
brane protein with a catalytic domain facing the extracellular
space. DPPIV knock-outmice show enhanced insulin secretion
and improved glucose tolerance (11, 12). This is due to cleavage
and, thus, inactivation of the incretin hormones glucagon-like
peptide and glucose-dependent insulinotropic polypeptide by
DPPIV (13–15). Therefore, DPPIV is used as a drug target for
the treatment of diabetes type 2.
In contrast, DPP8 and DPP9 are soluble cytoplasmic pepti-
dases of unknown function. They share 60% amino acid identity
and are ubiquitously expressed in vertebrate tissues (16–20).
Because DPP8 and DPP9 knock-out mice are not available,
most studies on these enzymeswere donewith inhibitors either
against the DPPIV family or specifically against DPP8 and -9.
Currently two specific DPP8/9 inhibitors are described (21, 22),
of which one showed severe effects in animal models (21).
Here we show that DPP9 is a rate-limiting enzyme for cyto-
solic post-proline aminodipeptidase activity. Our work associ-
ates an in vivo function with DPP9 in peptide degradation and
also suggests that changes in DPP9 expression levels or activity
contribute to changes in the repertoire of cytosolic peptides,
including those presented by MHC class I.
EXPERIMENTAL PROCEDURES
Antibodies—RU1 rabbit polyclonal antibody was produced
as described (23). Mouse monoclonal antibodies against -ac-
tin (clone AC-15) were purchased from Sigma. Anti--tubulin,
POP,DPP8, andDPP9 antibodieswere purchased fromAbcam.
Plasmids—Full-length human cDNAs for DPP8 and DPP9
(IRATp970G0924D6 and IRALp962J0230) were obtained from
the German Resource Center for Genome Research (RZPD).
For bacterial expression, DPP8 and DPP9 were cloned
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upstreamof an intein/chitin binding domain in the pTXB3 vec-
tor (Biolabs) using the EcoRI and SapI sites.
Peptides—The fluorogenic substrates GP-7-amino-4-meth-
ylcoumarin (AMC), WP-AMC, VP-AMC, DP-AMC, AAF-
AMC, succinyl-LLVY-AMC, andR-AMCwere purchased from
Biomol. MGP-AMC, KP-AMC, and GR-AMC were purchased
from Bachem. These derivatives were more than 90% pure. All
other peptides used in this study were purchased from Pepscan
and are at least 75% pure. By mass spectroscopy analysis, no
other major peptide species was detectable.
Inhibitors—The DPPIV-family inhibitor P32/98 was pur-
chased from Biomol. The DPP8/9-specific inhibitor described
as compound 2 in (21) was a kind gift from Jonathan Rosen-
blum, ActivX Biosciences. The proteasome inhibitor epoxomi-
cin was purchased from Calbiochem.
Cell Culture and siRNA Experiments—HeLa and 293-EBNA
cells were maintained in Dulbecco’s modified Eagle’s medium
with 10% fetal bovine serum. DPP8-1 siRNA (TGACGCCAC-
TAATTATCTA), DPP9-1 siRNA (TGCACTTTCTACAG-
GAATA), DPP9-2 siRNA (GCCACCAAGGUUUAUCCAA),
DPP9-3 siRNA (GGAUCAAUGUUCAUGACAU), and POP
siRNA (CAGGTTTGCAGAACCAGCGAGTATT) were pur-
chased from Invitrogen. For in vitro activity assays, HeLa cells
in 24-well plates were transfected with 20 nM siRNA using Oli-
gofectamine (Invitrogen) according to the manufacturer’s
instructions. 48 h after transfection, cells were split and retrans-
fected. Cells were trypsinized 72 h after initial transfection,
washed in phosphate-buffered saline, and resuspended in cold
TB buffer (20 mM Hepes, pH 7.3, 110 mM potassium acetate, 2
mM magnesium acetate, 0.5 mM EGTA, 1 mM dithiothreitol).
Cells were Dounce-homogenized and centrifuged at 100,000
g for 60 min to remove membranous organelles. Protein con-
tent of the supernatant was measured, and 5 g of protein
lysateswere tested for activity against 0.1mMXP-AMCat 30 °C.
Recombinant Protein Purification—DPP8 or DPP9 in pTXB3
was transformed into Escherichia coli BL21 (Stratagene). Cells
were grown to A600 0.8 and induced with 0.1 mM isopropyl
1-thio--D-galactopyranoside for 16 h at 15 °C. Cells were har-
vested and resuspended in lysis buffer (20mMHEPES, pH8, 500
mM NaCl, 0.1 mM EDTA), supplemented with 0.1% Triton-
X100, and disrupted by using an EmulsiFlex (Avestin). The
100,000  g supernatant was passed over chitin beads (New
England Biolabs) at 4 °C. Beads were washed at 4 °C with lysis
buffer and then at room temperature with the same buffer sup-
plemented with 10 mM MgCl2 and 5 mM ATP. Proteins were
eluted by incubation of the beads for 16 h at room temperature
with 20 mMHEPES, pH 8, 500 mMNaCl, 0.1 mM EDTA, 50 mM
dithiothreitol. Eluates were dialyzed against 20 mMHEPES, pH
8, 0.1mM EDTA, 1mM dithiothreitol and further purified using
anion exchange chromatography (Mono Q, GE Healthcare).
In Vitro Activity Assay—50 nM purified DPP8/9 was incu-
batedwith 200Mpeptide (VPYGSFKHV). Reactionswere car-
ried out for 2 h in TB buffer at 30 °C in the presence or absence
of 2.5 mM inhibitor (P32/98). Reactions were stopped by the
addition of trichloroacetic acid and centrifugation at 4 °C
(14,000  g 10 min). The supernatant was diluted 80-fold and
analyzed by matrix-assisted laser desorption ionization mass
spectrometry. 0.5–1-l samples were analyzed on a Bruker
Reflex IV (Bruker Daltonics, Bremen, Germany) in reflectron
mode using the thin-layer technique (24) for matrix prepara-
tion. Data processing was carried out using the XMass software
(Bruker Daltonics).
For fluorimetric assays, 50 nM purified enzyme was incu-
batedwith 15, 31, 62.5, 125, 250, or 500Mor 1mMGP-AMC in
a final reaction volume of 20l (Cliniplate 384-well plates, Lab-
systems) at 30 °C in TB buffer with 0.2% Tween and 0.2 mg/ml
ovalbumin. Fluorescence was measured using a Fluoroskan
Ascent microplate fluorimeter (Labsystems) with 380-nm
(excitation) and 450-nm (emission) filters and Ascent software.
Km, Vmax, kcat, and Ki values were calculated using the Prism
software. Each assay was repeated at least three times.
Competition Assays—Two peptide libraries were tested in
competition assays with GP-AMC, XPYGSFKHV and VPXGS-
FKHV, where X is 1 of 20 amino acids, as well as tumor antigen
peptides described under “Results.” 50 nM recombinant enzyme
was added to a premix of 100 M GP-AMC and 400 M test
peptide, and emission at 450 nm was measured after 5 min and
analyzed as described above. To determine the Ki of the tested
peptides, different concentrations of GP-AMC (15, 31, 62.5,
125, 250, and 500Mand 1mM)were added to 0, 200, or 400M
competing peptide, and GP-AMC hydrolysis was measured.
Each assay was repeated at least three times.
Cytolytic T Lymphocyte (CTL) Activity Assays—For CTL
activity assays, renal carcinoma cell line BB64-RCC (23) and
293-EBNA cells (Invitrogen) were grown in Iscove’s medium
(Invitrogen) supplemented with 10% fetal calf serum (Hyclone,
Logan), arginine (116 mg/liter), glutamine (219 mg/liter),
asparagine (36 mg/ml), and antibiotics. RU134–42 CTL clone
381/84was isolated and grown as described (23). Cells plated on
a 6-well plate were transfected with 40 nM DPP9-siRNAs or as
control enhanced GFP-siRNA (EGFP-S1 DS, IDTDNA). 24 h
later 293-EBNAcellswere transiently transfectedwithRU1 and
HLA-B51 encoding pcDNA3 plasmids (0.8 and 1.5 g/well,
respectively). 48 h after siRNA transfection, cells were har-
vested and plated in a 96-well plate (20–40,000 cells/well). For
control, one half of the wells were loaded for 1 h before the CTL
assaywith the antigenic peptide (VPYGSFKHV, 1g/ml).Next,
the CTL clone 381/84 was added (20,000 cells per well) in the
presence of interleukin-2 (25 units/ml). The supernatants were
collected 16 h later, and their interferon- content was meas-
ured by enzyme-linked immunosorbent assay (BIOSOURCE-
Invitrogen). To evaluate the efficiency of DPP9 silencing, ali-
quots of BB64 and 293-EBNA transfectants were collected
before the CTL assay. Cells were washed in cold phosphate-
buffered saline, lysed in TB buffer, centrifuged at 20,000 g for
20 min, and protein concentration was determined by BCA
(Pierce).
Treatment of 293-EBNA Cells with DPP8/9 Inhibitor—293-
EBNA cells growing in 6-well plates (2 106/well) were trans-
fected with pCDNA3 plasmids coding for RU1 (0.8 g/well),
MAGE-A3 (0.8 g/well), HLA-B51 (1.1 g/well), and HLA-A1
(1.1g/well) using Lipofectamine. 16 h laterMHC-bound pep-
tides were eluted from the cells by incubation with a citrate
buffer, pH 3, for 1.5 min at room temperature. Cells were then
returned to fetal calf serum-free medium (X-vivo 10) at 37 °C.
2 h later cells were washed in phosphate-buffered saline and
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resuspended in a low conductivity
cytoporation buffer at 107 cells/ml.
Cell suspensions (200 l) were elec-
troporated (200 V, 300 microfarads,
100 ohms) either with DMSO
(mock treatment) or with 100 M
DPP8/9 inhibitor (stock at 20 mM in
DMSO). Electroporated cells were
incubated for 4 h in fetal calf serum-
free medium (X-vivo 10). Mock-
treated cells were then treated
either with 0.5% DMSO (negative
control), 1 M epoxomicin, or 100
M DPP8/9 inhibitor. Cells resus-
pended in CTL medium were split
in two parts, and 5 g/ml concen-
trations of antigenic peptides
(RU134–42 or MAGE-A3168–176)
was added during 1 h. Cells washed
in the CTL medium were used as
targets for a CTL assay (40,000 tar-
gets for 20,000 CTLs) by the addi-
tion of the CTL clones 381/84 or
A10. Each condition was tested in
triplicate. To evaluate the efficiency
of DPP8/9 inhibition, aliquots of the
inhibitor-treated 293-EBNA cells
were collected before the CTL
assay. Cells were washed in cold
phosphate-buffered saline, lysed in
TB buffer, centrifuged at 20,000 g
for 20 min, and protein concentra-
tion was determined by BCA
(Pierce). Cell extracts (5 g) were
tested for GP-AMC degradation as
described above.
RESULTS
DPP9 Is a Rate-limiting Post-pro-
line Aminodipeptidase in Cytosolic
Extracts—Most cytosolic pepti-
dases are inactive toward the amino
acid proline because of the rigid
geometric configuration of the
prolyl-peptide bond. Nevertheless,
the artificial substrate Gly-Pro-
AMC (GP-AMC) is rapidly
degraded in cytosolic extracts, as
can be measured by the release of
the fluorescent product AMC upon
cleavage (Fig. 1A). Three post-pro-
line peptidases are known to local-
ize to the cytosol, POP, DPP8, and
DPP9. Currently the function of
DPP8 and DPP9 is not understood.
We tested their contribution to the
degradation of proline-containing
peptides using a highly specific
FIGURE 1.Amajor fractionof cytosolic post prolinepeptidase activity is contributedbyDPP9.A, left, 5g
of cytosol from HeLa cells were tested for the cleavage of R-AMC, GP-AMC, and AAF-AMC. Reactions were
performed for the indicated times, and fluorescence was measured using 380-nm (excitation) and 450-nm
(emission) filters. Right, 5 g of HeLa cell cytosol were treated with the indicated concentrations of a specific
DPP8/9 inhibitor (compound 2) before the addition of 250 M GP-AMC. B, HeLa cells were transfected with
siRNA against POP, DPP8, DPP9, or control siRNA and harvested after 72 h. Shown is a Western blot of cytosol
extracts from the siRNA treated cells (10 g of protein extract per lane) developed with antibodies against
DPP8, DPP9, POP and tubulin as a loading control. Cytosol fractions from silenced cells were then tested for
release of AMC fromGP-AMC, KP-AMC, VP-AMC,WP-AMC, andDP-AMCas inA (5gof cytosolic fractionswere
used per reaction).C, cells were transfectedwith three different DPP9 siRNAs or control siRNA and analyzed for
activity against GP-AMC as in A. A Western blot is shown to confirm the down-regulation of DPP9 in the
analyzed fractions, developedwith antibodies againstDPP9 and tubulin. All kinetic assays (A–C) were repeated
at least three times in triplicate; shown are results of one triplicate assay.D, to estimateDPP8 andDPP9 protein
levels at steady state, three different concentrations of HeLa total cell lysates (5, 10, or 20 g) and defined
concentrations of recombinant (rec) DPP8 (1, 5, 10, 20 ng) or DPP9 (5, 10, 20, 40 ng) purified from E. coli were
compared by immunoblotting with DPP8- or DPP9-specific antibodies.
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DPP8/9 inhibitor, previously described as compound 2 by Lan-
kas et al. (21). As shown in Fig. 1A, the addition of the DPP8/9
inhibitor to cytosolic extracts strongly inhibits GP-AMC deg-
radation, suggesting that these peptidases and not POP are
responsible for GP-AMC cleavage.
To differentiate between DPP8 and DPP9, HeLa cells were
transfected for 72 h with DPP8 or DPP9 siRNA. For control,
cells were transfected with siRNA against POP and a non-tar-
geting siRNA. Cytosolic extracts of the silenced cells were then
tested forGP-AMCcleavage. Depletion of POPorDPP8 had no
significant effect on the cleavage of GP-AMC compared with
treatment with control siRNA (Fig. 1B). On the other hand,
depletion of DPP9 strongly reduced release of AMC from GP-
AMC, suggesting that DPP9 is rate-limiting for cleavage of this
peptide in HeLa cell lysates. Peptides that lack proline such as
Gly-Arg-AMC, Arg-AMC, Ala-Ala-Phe-AMC, and N-succi-
nyl-Leu-Leu-Val-Tyr-AMC were not stabilized in cells treated
with siRNA against DPP8, DPP9, or POP (data not shown).
To test whether DPP9 is also rate-limiting for other proline-
containing peptides, cytosolic extracts were tested for the
degradation of Val-Pro-AMC (VP-AMC), Trp-Pro-AMC (WP-
AMC), Lys-Pro-AMC (KP-AMC), and Asp-Pro-AMC (DP-
AMC). Although Asp-Pro-AMC (DP-AMC) appeared to be
very stable comparedwith the otherXP-AMC substrates tested
andwas not affected byDPP9 silencing, all otherXP-AMC sub-
strateswere significantly stabilized inDPP9- but not inDPP8 or
POP-silenced cells (Fig. 1B).
To ensure that the stabilizing effect of DPP9 silencing on
XP-AMC substrates was not due to off-target effects, we
repeated the experiment using two additional DPP9 siRNAs.
Each of the three siRNAs led to strong reduction of post-proline
cleavage activity in cell lysates, and the extent of reduction cor-
relatedwell with the reduction inDPP9 levels (compare activity
assays in Fig. 1Cwith the correspondingWestern blot). Similar
effects for DPP9 silencing were observed also in 293-EBNA
cells (supplemental Fig. 2).
Next we compared the protein levels of DPP8 and DPP9
using recombinant enzymes for normalization of the antibody.
In several different cell lines DPP9 is a very abundant protein
accounting for up to 0.4% of total cellular proteins (Fig. 1D and
supplemental Fig. 3). In contrast, full-length DPP8 is barely
detected in cellular lysates. A slightly shorter band which dis-
appears under siRNA treatment can be detected in most cell
lines tested. Whether this band represents a splice variant or a
limited proteolysis product of DPP8 is currently unknown.
However, its levels are still10-fold lower than those of DPP9.
Next we verified that DPP9 cleaves GP-AMC, KP-AMC,
WP-AMC, VP-AMC, and DP-AMC using in vitro assays with
recombinant enzyme, which was expressed and purified from
E. coli (Fig. 2). In accordance with the relatively high stability of
DP-AMC in cell lysates, we find that it is the least efficient
substrate for recombinant DPP9. Peptides that did not contain
a proline residue were not degraded by DPP9 (not shown).
Taken together, these findings suggest that at least 80% of the
cytosolic post-proline cleavage activity measured on the artifi-
cial substrates GP-AMC, KP-AMC, VP-AMC, and WP-AMC
can be attributed to DPP9.
Proline-containing Antigen-putative Substrates for DPP9—
So far no physiological or natural substrates of DPP8 or DPP9
have been identified. However, our data suggest that DPP9 is
necessary for cleavage of many different proline-containing
peptides, implying a housekeeping function for DPP9 in pep-
tide turnover. If this is the case, DPP9 may also influence the
pool of antigenic peptides that are loaded on MHC class I, as
some of the peptides that emerge from the proteasome are used
for antigen presentation. For binding to MHC class I, peptides
typically require a length of 8–10 amino acids. Because protea-
somal products are often longer (2, 3), they are trimmed on
the N terminus either after translocation into the ER (25–28)
or in the cytoplasm by amino- and endopeptidases (29–35).
Antigen peptides with a proline residue in second position
are frequently found in association with HLA-B7, HLA-B8
HLA-B15, HLA-B51, HLA-B35, and HLA-B53 (36). Hence,
such antigens are putative in vivo substrates for DPP8 and
DPP9.
We selected several known peptide antigens that contain an
anchor proline residue in position two (www.cancerimmunity.
org/peptidedatabase/Tcellepitopes.htm) and tested them in
competition assays with GP-AMC. Michaelis-Menten analysis
shows that each of these peptides acts as a competitive inhibi-
tor, albeit with different efficiency (Fig. 3 and data not shown).
Tumor-associated antigens from mutated CASP-8 (476FPSD-
SWCYF484) and gp100 (471VPLDCVLYRY480) are very efficient
competitors, and gp100 (630LPHSSSHWL638) and LAGE-2
(94MPFATPMEA102) compete well, whereas the LAGE-1 anti-
gen (46APRGVRMAV54) is a poor competitor (Ki values varied
between 3.6 and 381M). For control we used proline-free pep-
tides, which did not inhibit AMC release from GP-AMC (con-
trol peptides 1 and 2, Fig. 3). The dipeptide GP, which is the
product of GP-AMC cleavage, did not cause product inhibi-
tion. Based on these findings, DPP9 appears to be able to
cleave a wide range of naturally occurring peptide antigens
FIGURE 2. In vitro processing of XP-AMC substrates by recombinant DPP9. Left, Coomassie staining of recombinant DPP9, expressed and purified from
E. coli. The graph shows the results of a Michaelis-Menten assay performed as a triplicate assay using 50 nM DPP9 and varying concentrations of the XP-AMC
substrate. The table shows calculated kcat, Km, and kcat/Km results for different substrates. Values were calculated using non-linear regression (Prism software).
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with proline in second position but shows significant sub-
strate preference.
DPP8 and DPP9 Display Similar Substrate Specificity—Next
we asked whether DPP8 and DPP9, which that are 60% identi-
cal, have overlapping substrate specificity. To get insights into
parameters that determine efficient cleavage by DPP8 and
DPP9, we carried out a detailed competition analysis with pep-
tides that vary only in one amino acid. As described above,
selected antigens competed with GP-AMC for cleavage by
DPP9, but they varied significantly in efficiency. As a model
substrate we chose the RU134–42 antigen (VPYGSFKHV) as it
had the potential to be a physiological substrate (see below).
First, we confirmed that the VPYGSFKHV peptide is indeed
cleaved by recombinant DPP8 and DPP9. Mass spectrometry
analysis revealed that both enzymes remove the first two amino
acids from theVPYGSFKHVpeptide (supplemental Fig. 4,A,B,
and D). Proteolytic cleavage was blocked by isoleucine-thiazo-
lidide (P32/98), a specific competitive inhibitor for peptidases
of the DPPIV family, including DPP8 and DPP9 (supplemental
Fig. 3,C and E) (21).We then tested 20 variants of the RU134–42
peptide, differing only in the first amino acid, in competition
studies (Fig. 4,A (for DPP9) and B (for DPP8)).Michaelis-Men-
ten analysis demonstrated that the peptides act as competitive
inhibitors of GP-AMC (data not shown). Based on these data,
DPP8 andDPP9 showed very similar catalytic preferences. Both
prefer substrates with an aromatic (Phe, Tyr, Trp) or branched
aliphatic (Val, Ile) amino acids at the first position. Poor com-
petitors are acidic residues (Glu and Asp), which is in line with
our observation of the highKm for the degradation of DP-AMC
by DPP9. Next we tested whether DPP9 has preferences for the
amino acid after proline by using variants of the RU1 peptide
that differ in the third amino acid (P2). The only peptide that
was a poor competitorwasVPPGSFKHV, suggesting thatDPP9
cannot cleave a Pro-Pro bond (Fig. 4C).
DPP9 Restricts MHC Class I Presentation of a Proline-con-
tainingAntigen—Formost antigens it is unknownwhether they
are generated in the cytoplasm, where they could encounter
DPP8 and DPP9, or whether they are matured in the ER. An
exception is RU134–42 (VPYGSFKHV) (23), an antigenic pep-
tide that was shown to be produced in the cytoplasm (37).
RU134–42was discovered as an antigen presented byMHCclass
I to CTLs raised against a renal carcinoma cell line (23).
Our competition assays in Figs. 3 and 4 suggest that the
RU134–42 antigenic peptide VPYGSFKHV is an efficient sub-
strate for DPP8 and DPP9 in vitro. Because DPP8, DPP9, and
the RU134–42 peptide are present in the cytoplasm (16–18, 37),
we asked whether RU134–42 is an in vivo substrate for both
enzymes. Production and stability of the RU134–42 antigen can
be assessed indirectly due to its presentation on the cell surface
by MHC class I allele HLA-B51 to a cytolytic T lymphocyte
FIGURE 3.Antigens containing proline at position 2 are competitive sub-
strates for DPP9. GP-AMC (100 M) was mixed with a competing peptide
(400 M) before the addition of 50 nM recombinant DPP9. AMC release was
measured after 5min using 380 nm (excitation) and 450 nm (emission) filters.
Sequence of control peptides 1 and 2 are EQKLISEEDL and DYKDDDDK,
respectively. Ki values were calculated using detailedMichaelis-Menten anal-
ysis in competition assays with GP-AMC (bymixing 0, 100, or 500M peptide
with varying concentrations of GP-AMC) using the Prism software. Each
experimentwas repeated at least four times (each in triplicate); shownare the
results of one experiment done in triplicate.
FIGURE 4. Recombinant DPP8 and DPP9 share similar substrate specific-
ity. Two peptide libraries were tested in competition assays with GP-AMC,
XPYGSFKHV and VPXGSFKHV, where X is one of 20 amino acids. GP-AMC (100
M) was mixed with a competing peptide (400 M) before the addition of 50
nM recombinant DPP8 or DPP9. AMC release was calculated 5 min after initi-
ation of reaction. Relative AMC releasewas calculated by setting AMC release
in the absenceof competingpeptide to 100%.A, competition assays forDPP9
with peptide library XPYGSFKHV. B, competition assays forDPP8with peptide
library XPYGSFKHV. C, competition assays for DPP9 with peptide library
VPXGSFKHV. Each experiment was performed at least four times, each in trip-
licate. Shown are the results of a triplicate.
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(CTL clone 381/84)(23). The CTL recognition can be moni-
tored by measuring the interferon- produced by the activated
CTLs. If DPP8 and/orDPP9 efficiently cleave theVPYGSFKHV
peptide in vivo, then reduced levels or activity of these pepti-
dases should lead to increased presentation of the RU134–42
antigen on the cell surface.
To test this hypothesis, we analyzed the effect of the DPP8/
9-specific inhibitor (compound 2 (21)) on the presentation of
the RU134–42 antigen to T-cells. To confirm inhibitor uptake,
the degradation of GP-AMC was measured in extracts of
treated cells. Surprisingly, we found that incubation of cells
with 100 M DPP8/9 inhibitor for 2 h did not affect the degra-
dation of GP-AMC, suggesting that the inhibitor may not have
entered the cells. On the other hand, cells electroporated with
100 M DPP8/9 inhibitor showed a strong reduction in the
degradation of GP-AMC in comparison to control cells that
were electroporated with DMSO only (Fig. 5C).We then tested
the capacity of the inhibitor-treated cells to present the
RU134–42 antigen.As shown in Fig. 5, cells that showed reduced
GP-AMC degradation (DPP8/9 inhibitor was electroporated)
weremore potent in presentation of the RU134–42 antigen (Fig.
5, A and C). This suggests increased stability of the RU134–42
antigen (VPYGSFKHV) due to inhibition of DPP8 and -9. We
controlled the antigen production process by adding a specific
proteasome inhibitor, epoxomicin, to the cells, as the 26 S pro-
teasome is necessary for producing the C terminus of the
RU134–42 antigen (23). Accordingly, treatment of cells with this
inhibitor led to reduced presentation of the RU134–42 antigen
and increased the stability of the proteasome substrate N-suc-
cinyl-Leu-Leu-Val-Tyr-AMC in cell lysates (Fig. 5,A andC). To
control the specificity of the inhibitors, we followed the presen-
tation of a tumor antigen MAGE-A3168–176 that does not
require the 26 S proteasome or serine peptidases for its presen-
tation (Parmentier N).5 As expected,MAGE-A3168–176 presen-
tationwas unaffected by either inhibitor (Fig. 5,B andC). These
results suggest that the RU134–42 antigen is an in vivo substrate
of DPP8 and DPP9.
To differentiate between both enzymes we transfected DPP8
or DPP9 siRNA into the renal carcinoma cell line BB64-RCC in
which the RU1 antigen was originally identified (23). Two days
later, when DPP8 and DPP9 levels were efficiently down-regu-
lated (Fig. 6, A and B), cells were tested for recognition by CTL
clone 381/84. As shown in Fig. 6B, silencing of DPP8 did not
have an effect on the presentation of the peptide compared
with control cells transfected with a siRNA specific for
enhanced GFP. However, we observed that interferon- pro-
duction was two times higher with DPP9-silenced cells com-
pared with the control cells (Fig. 6A). These results were
confirmed using a second cell line, 293-EBNA cells, and
three different DPP9-specific siRNAs. Because 293-EBNA
cells do not express RU1 or HLA-B51, the expression of
5 N. Parmentier and B. J. Van den Eynde, manuscript in preparation.
FIGURE 5. Administration of a DPP8/9-specific inhibitor to cells leads to increased presentation of the RU134–42 antigen. A, 293-EBNA cells were
transiently transfected with plasmids expressing RU1 and HLA-B51. 48 h later cells were treated for 2 h with either 1 M concentrations of the proteasome
inhibitor epoxomicin (Epoxo) or 100 M DPP8/9 specific inhibitor (m. DPP8/9), which was added to the medium. Alternatively, cells were electroporated with
100MDPP8/9 inhibitor (e. DPP8/9) or DMSO for control. Two hours later CTL clone 381/84was added to the cells, and INF- releasewasmeasured (black bars,
right graph). Saturating amounts of the antigenic peptide were added to cells before incubation with CTL clone 381/84 (white bars, right graph) to assess their
viability. Shownon the left side is a simplifiedpresentationof the inhibitor effect on thepeptidepresentation. It consists of the ratiobetween INF- release from
tested cells (black bars, right graph) dividedby INF- release from the control cells thatwere incubatedwith saturating amounts of thepeptidebefore the assay
(white bars, right graph). Each experiment was repeated at least three times, each time in triplicate (shown is one experiment in triplicate). The error bars show
S.D. of the triplicates. B, cells in Awere tested for their capacity to present MAGE-A3168–176 to HLA-A1 using CTL clone A10. CTL clone A10 was isolated from a
HLA-A1melanoma patient vaccinated with a recombinant pox virus encoding MAGE-A3168–176 C, lysates of cells in A (5 g) were tested for activity against
5 M GP-AMC, 50 M succinyl-LLVY-AMC, and 5 M R-AMC. Each assay was repeated three times.
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RU134–42 was induced using plasmids encoding both pro-
teins. Again, in contrast to DPP8, DPP9 silencing resulted in
increased interferon- production by the CTLs compared
with cells transfected with control siRNA (p values were
lower than 0.001). Silenced cells and control cells incubated
with saturating amounts of the RU1 peptide were equiva-
lently recognized by clone 381/84, indicating that DPP8/9-
silencing did not affect cell viability (Fig. 6, right panel, white
bars). The increase in RU1 presentation was not due to
higher levels of the RU1 protein in DPP9-silenced cells (Fig.
6A). These observations let us to conclude that the RU134–42
antigen is a natural substrate for DPP9 and that endogenous
DPP9 limits the presentation of this antigenic peptide.
DISCUSSION
DPP9 Accounts for Most Post-proline Dipeptidase Activity in
the Cytoplasm—Most cytoplasmic peptidases cannot cleave
after the amino acid proline, with the exception of POP, DPP8,
and DPP9. Here we show that DPP9 is responsible for most
cytosolic post-proline peptidase activity, at least on selected
targets. Administration of a DPP8/9-specific inhibitor to HeLa
and 293-EBNA cells strongly reduces the degradation of GP-
AMC. In addition, depletion of DPP9, but not of DPP8 or POP,
from HeLa and 293-EBNA cell extracts decreases the cleavage
rates of severalXP-AMC substrates. Finally, administration of a
DPP8/9 inhibitor or siRNA treatment against DPP9 but not
DPP8 protects the RU134–42 antigen from degradation both in
BB64RCC as well as 293-EBNA cells. Hence, although recom-
binantDPP8 andDPP9 have very similar substrate specificity in
vitro, their relative contributions both in extracts and in intact
cells are very different. Consistent with this, DPP9 is much
more abundant than DPP8 in several different cell lines includ-
ing HeLa, 293-EBNA, and BB64RCC cells (supplemental Fig. 3
and data not shown). Taken together our data suggest a corre-
lation between protein levels and enzymatic contribution of
DPP8 andDPP9.With respect to development of specific inhib-
itors, it will be important to compare protein levels ofDPP8 and
DPP9 in different tissues but also throughout development and
during stress conditions.
Substrate Specificity of DPP8 and DPP9—As revealed by
competition assays, DPP8 andDPP9 have very similar substrate
specificity. A key determinant for efficient cleavage by DPP8
andDPP9 is the first amino acid. Substrates with an aromatic or
branched aliphatic amino acid at the first position are clearly
preferred, whereas acidic residues are disfavored. These results
are in agreement with a recent publication that determined the
degradation of peptide libraries by DPP8 and DPP9 expressed
FIGURE 6. The RU134–42 antigen is a substrate for DPP9 in vivo. A, BB64-RCC and 293-EBNA cells were transfected with siRNA against DPP9 or against GFP
as control. 24 h later 293-EBNA cells were transiently transfected with plasmids expressing RU1 and HLA-B51 (BB64-RCC express RU1 and HLAB51 endog-
enously). CTL clone 381/84 was added to the cells, and INF- release was measured (black bars, right graph). As a control, saturating amounts of the antigenic
peptidewere added to cells before incubationwithCTL clone381/84 (white bars, right graph) to assess the viability after siRNA treatment. Shownon the left side
is a simplified presentation of the siRNA effect on the peptide presentation. It consists of the ratio between INF- release from tested cells (black bars, right
graph) divided by INF- release from the control cells that were incubated with the peptide before the assay (white bars, right graph). Each experiment was
repeated at least three times, each time in triplicate (shown is one experiment in triplicate). The error bars show S.D. of the triplicates. Shown is aWestern blot
analysis of the cells used as targets in the CTL assay. -Actin was used as a loading control. B, same experiment as in A, except that cells were transfected with
siRNA against DPP8 or GFP for control.
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and purified from HEK293T cells (38). With the exception of
proline, any amino acid is tolerated at the third position. Addi-
tional parameters such as length and/or C-terminal residues
also seem to contribute to recognition and cleavage efficiency;
although the gp100 antigen VPLDCVLYRY shares the first
amino acid with the RU134–42 peptide, it is a much better com-
petitor for GP-AMP (5-fold lower Ki). Full understanding of
substrate preferences may require extensive analysis of hun-
dreds of peptides or cocrystallization of DPP9 with model
substrates.
A Role for DPP9 in Antigen Presentation—Antigenic peptides
with proline in P2 are frequently found in association with HLA-
B7, HLA-B8 HLA-B15, HLA-B51, HLA-B35, and HLA-B53 (36).
However, such peptides are not efficiently transported through
transporter associated with antigen processing into the ER unless
proline is compensated for by additional favorable amino acids
(39–42). It is, therefore, assumed that most antigens with proline
in P2 are transported as N-terminal-extended precursors into the
ER where they are further processed by ERAP1/ERAAP and
ERAP2 (26, 27, 43). Although the site of maturation is unknown
for most antigens, RU134–42 maturation was shown to take place
in thecytoplasm.The finalRU134–42peptide (VPYGSFKHV) can
then enter the ER where it associates with MHC class I mole-
cules (37). In line with these results, we find that silencing or
inhibition of the cytoplasmic peptidase DPP9 results in
increased presentation of the RU134–42 peptide. Our data sug-
gest thatmodulation in the expression levels or activity ofDPP9
can determine whether the RU134–42 peptide is destroyed or
presented at the cell surface and strengthen previous findings
that proline-containing antigens can be matured in the cyto-
plasm and then transported into the ER. It will be interesting to
see whether the RU134–42 antigen is an exception or whether
many proline-containing antigensmature in the cytoplasm and
are, thus, putative substrates for DPP9.
In conclusion, ourwork assigns a biological function toDPP9
as a rate-limiting enzyme for degradation of cytosolic proline-
containing peptides. We have characterized the first endoge-
nous substrate for DPP9 and added the enzyme to the short list
of peptidases implicated in antigen presentation. From these
findings we predict that DPP9 contributes both positively and
negatively to the repertoire of peptides that is available for
MHCclass I presentation; antigens containingXaa-Pro, such as
RU134–42, could be destroyed by DPP9 (Fig. 7, peptide A),
whereas antigen precursors with anN-terminal Xaa-Pro dipep-
tide may need DPP9 for their maturation (Fig. 7, peptide B).
Whether DPP8 functions in a more specialized pathway or
whether it plays a similar role to DPP9 is still an open question.
Future work will be aimed at investigating whether changes in
the activity of DPP8 and DPP9 due to physiological regulation
pathophysiological changes, or drug treatment do indeed con-
tribute to significant changes in the peptide repertoire pre-
sented by MHC class I. If so, DPP8 and DPP9 may be useful
drug targets in immune-related disorders (discussed in Refs. 10
and 44). Application of the DPP8/9 inhibitor (compound 2)
used in this study was previously reported to attenuate T-cell
activation (21). However, experiments done by us and others
(22) using the same inhibitor suggest that this inhibitor is not
(easily) cell-permeable. Therefore, development of DPP8- and
DPP9-specific cell-permeable inhibitors would be very impor-
tant tools to further study the contribution of these two
enzymes in cells and animal models.
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